Abbott Laboratories
ABT
$105.64
-$0.26-0.25%
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 1.49% | -2.56% | -11.36% | -18.06% | -12.01% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.49% | -2.56% | -11.36% | -18.06% | -12.01% |
| Cost of Revenue | -0.07% | -0.52% | -9.12% | -13.50% | 5.22% |
| Gross Profit | 2.75% | -4.20% | -13.11% | -21.35% | -22.38% |
| SG&A Expenses | -5.74% | -1.07% | -1.21% | -2.72% | -6.75% |
| Depreciation & Amortization | -3.02% | -0.40% | -1.78% | -4.10% | -3.50% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -1.91% | -1.92% | -5.24% | -9.17% | -2.01% |
| Operating Income | 17.68% | -5.50% | -33.00% | -44.27% | -40.83% |
| Income Before Tax | 35.98% | -4.95% | -30.44% | -45.69% | -43.27% |
| Income Tax Expenses | -29.97% | -27.24% | -21.86% | -43.12% | -15.09% |
| Earnings from Continuing Operations | 54.31% | 0.07% | -31.86% | -46.14% | -48.06% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 54.31% | 0.07% | -31.86% | -46.14% | -48.06% |
| EBIT | 17.68% | -5.50% | -33.00% | -44.27% | -40.83% |
| EBITDA | 12.33% | -3.50% | -25.45% | -35.21% | -33.41% |
| EPS Basic | 54.85% | 0.96% | -31.28% | -45.56% | -47.22% |
| Normalized Basic EPS | 13.49% | -4.16% | -29.90% | -43.33% | -38.75% |
| EPS Diluted | 55.01% | 1.23% | -31.58% | -45.23% | -47.23% |
| Normalized Diluted EPS | 13.49% | -4.11% | -29.83% | -43.26% | -38.75% |
| Average Basic Shares Outstanding | -0.34% | -0.81% | -0.77% | -1.14% | -1.57% |
| Average Diluted Shares Outstanding | -0.34% | -0.87% | -0.86% | -1.28% | -1.57% |
| Dividend Per Share | 7.84% | 8.51% | 8.51% | 8.51% | 8.51% |
| Payout Ratio | -0.30% | 0.07% | 0.58% | 0.99% | 0.99% |
